



M E M O R A N D U M

TO: Valued CHIP, STAR and STAR+PLUS Providers

FROM: El Paso Health

DATE: 2/05/2025

RE: VDP to Begin Mailing 'Under-Treatment of Chronic Hepatitis C Virus Infections' Retrospective Drug Ut

VDP to Begin Mailing “Under-Treatment of Chronic Hepatitis C Virus Infections” Retrospective DUR Intervention Information

VDP contracted with AbbVie to improve awareness, screening, diagnosis, and treatment of the Hepatitis C Virus (HCV). HCV is a liver infection caused by a virus and often develops into a long-term or chronic illness. If untreated, HCV can cause significant damage to the body, such as liver cancer and cirrhosis. VDP presented a retrospective drug utilization review intervention for the Under-Treatment of Chronic Hepatitis C Virus Infections at the Drug Utilization Review Board (DURB) meeting held on Oct. 25, 2024. The DUR Board approved the intervention.

Key Details:

To improve awareness, screening, diagnosis, and treatment of HCV for Medicaid clients, VDP has conduct outreach and mailed the intervention letters to identified fee-for-service and El Paso Health providers on Jan. 24, 2025.

If you have any questions regarding this communication please contact our Provider Relations team at 915-532-3778 or email us at ProviderRelationsDG@elpasohealth.com.